BioSpace News Archive

Puma Biotechnology, Inc., a biopharmaceutical company, presented final results from the Phase II SUMMIT ‘basket’ trial, assessing the efficacy of neratinib in treatment-refractory patients with metastatic biliary tract cancers with somatic HER2 mutations at the 2022 American Society of Clinical Oncology Annual Meeting.

New data presented at the 82nd Scientific Sessions of the American Diabetes Association® revealed the incidence of severe diabetic ketoacidosis among children with type 1 diabetes was significantly higher during the pandemic compared to pre-pandemic.

Two studies provide evidence that social determinants of health account for disparities in health outcomes related to diabetes.

A Centers for Disease Control and Prevention study provides new insights into vision impairment prevalence over the last 20 years.

Nucleai announced that it will share new data at the American Society of Clinical Oncology 2022 Annual Meeting in an online publication on an exploratory analysis of a phase 2 study to find new pathology-based predictive biomarkers for DLBCL, the most common type of Non-Hodgkin’s lymphoma.

CG Oncology, Inc., a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, announced interim data on two ongoing clinical studies will be presented at The American Society of Clinical Oncology 2022 Annual Meeting.

Vera Therapeutics, Inc. announced that interim data from the Phase 2 trial of MAU868 versus placebo to treat BK Virus in kidney transplant patients showed that MAU868 was well tolerated and demonstrated significant BK antiviral activity in kidney transplant recipients with BK viremia.

Kite, a Gilead Company, announced longer-term follow-up results from two pivotal studies of the CAR T-cell therapy Tecartus®.

Curis, Inc. announced the presentation of encouraging clinical data from both the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology Annual Meeting currently taking place in Chicago and online until June 7, 2022.

Legend Biotech Corporation, a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, presented new and updated results from the CARTITUDE clinical development program studying ciltacabtagene autoleucel in the treatment of multiple myeloma at the 2022 American Society of Clinical Oncology Annual Meeting.